NEW YORK (GenomeWeb News) – Horizon Discovery today announced it has signed an agreement with Bayer Pharma for the use of Horizon's Genesis genome editing technology in support of Bayer's cancer R&D programs.
Horizon will use its platform to develop human isogenic cell lines for use in Bayer's programs in order to deliver cell lines that more accurately model the disease-relevant mutations found in human tumors.
Genesis allows for the alteration of endogenous gene sequence of human and mammalian cell lines without unwanted or confounding genotypes and/or phenotypes and can more accurately reflect patient genotypes in human cancer cell lines derived from human tumors, Horizon said.
Financial and other terms of the deal were not disclosed.